ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC

Share this content:
ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC
ASCO: Pembrolizumab Superior for Initial Tx of Advanced NSCLC

MONDAY, June 4, 2018 (HealthDay News) -- For patients with programmed death ligand 1 (PD-L1)-expressing locally advanced or metastatic non-small-cell lung cancer (NSCLC), pembrolizumab is associated with better overall survival than chemotherapy, regardless of the PD-L1 tumor proportion score (TPS), according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.

Gilberto Lopes, M.D., from the University of Miami Health System, and colleagues compared pembrolizumab with platinum-based chemotherapy at the lower TPS of ≥1 percent. A total of 1,274 patients with previously untreated advanced/metastatic NSCLC were randomized in a 1:1 ratio to ≤35 cycles of pembrolizumab or no more than six cycles of paclitaxel + carboplatin or pemetrexed + carboplatin with optional pemetrexed maintenance.

The researchers found that 13.7 and 4.9 percent of patients were still on pembrolizumab and were on pemetrexed maintenance, respectively, after a median follow-up of 12.8 months. In patients with TPS ≥50 percent, TPS ≥20 percent, and TPS ≥1 percent, pembrolizumab correlated with significant improvement in overall survival (hazard ratios, 0.69, 0.77, and 0.81, respectively). The frequency of grade 3 to 5 drug-related adverse events was reduced with pembrolizumab (17.8 versus 41.0 percent).

"Our study shows that pembrolizumab provides more benefit than chemotherapy for two-thirds of all people with the most common type of lung cancer," Lopes said in a statement.

Several authors disclosed financial ties to pharmaceutical companies, including Merck, which manufactures pembrolizumab and partially funded the study.

Press Release
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Warns About 'Miracle' Young Blood Infusion Treatments

FDA Warns About 'Miracle' Young Blood Infusion Treatments

Expensive 'fountain of youth' therapies are unproven, potentially harmful

CDC: Salmonella Cases Tied to Raw Turkey Products Now at 279

CDC: <i>Salmonella</i> Cases Tied to Raw Turkey Products ...

Cases reported in 41 states and the District of Columbia; 107 people have been hospitalized

Chronic Wasting Disease Found in Deer in 24 States

Chronic Wasting Disease Found in Deer in 24 ...

No evidence disease can spread to humans, but hunters should be careful around potentially infected animals

is free, fast, and customized just for you!




Already a member?

Sign In Now »